![](/images/graphics-bg.png)
Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective
المؤلفون المشاركون
Silverman, Stuart
Agodoa, Irene
Kruse, Morgan
Parthan, Anju
Orwoll, Eric S.
المصدر
العدد
المجلد 2015، العدد 2015 (31 ديسمبر/كانون الأول 2015)، ص ص. 1-9، 9ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2015-12-09
دولة النشر
مصر
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
Purpose.
To evaluate the cost-effectiveness of denosumab versus other osteoporotic treatments in older men with osteoporosis from a US payer perspective.
Methods.
A lifetime cohort Markov model previously developed for postmenopausal osteoporosis (PMO) was used.
Men in the model were 78 years old, with a BMD T-score of −2.12 and a vertebral fracture prevalence of 23%.
During each 6-month Markov cycle, patients could have experienced a hip, vertebral or nonhip, nonvertebral (NHNV) osteoporotic fracture, remained in a nonfracture state, remained in a postfracture state, or died.
Background fracture risks, mortality rates, persistence rates, health utilities, and medical and drug costs were derived from published sources.
Previous PMO studies were used for drug efficacy in reducing fracture risk.
Lifetime expected costs and quality-adjusted life-years (QALYs) were estimated for denosumab, generic alendronate, risedronate, ibandronate, teriparatide, and zoledronate.
Results.
Denosumab had an incremental cost-effectiveness ratio (ICER) of $16,888 compared to generic alendronate and dominated all other treatments.
Results were most sensitive to changes in costs of denosumab and the relative risk of hip fracture.
Conclusion.
Despite a higher annual treatment cost compared to other medications, denosumab is cost-effective compared to other osteoporotic treatments in older osteoporotic US men.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Silverman, Stuart& Agodoa, Irene& Kruse, Morgan& Parthan, Anju& Orwoll, Eric S.. 2015. Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective. Journal of Osteoporosis،Vol. 2015, no. 2015, pp.1-9.
https://search.emarefa.net/detail/BIM-1069916
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Silverman, Stuart…[et al.]. Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective. Journal of Osteoporosis No. 2015 (2015), pp.1-9.
https://search.emarefa.net/detail/BIM-1069916
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Silverman, Stuart& Agodoa, Irene& Kruse, Morgan& Parthan, Anju& Orwoll, Eric S.. Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective. Journal of Osteoporosis. 2015. Vol. 2015, no. 2015, pp.1-9.
https://search.emarefa.net/detail/BIM-1069916
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1069916
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)